SG7001 Managing Strategy Operations and Partnerships

Vision Extend the projects beyond Libya by adding resources and activities that were earlier, restricted to customers’ satisfaction and improvement along with continuing the medical education via science-related events by pharmacists and physicians (Sothema, 2022).
Purpose The main purpose of the company is to make medicines easily accessible to the majority of African populations (Sothema, 2022).
  Quality: 4Vs
QUALITY EVALUATION DESCRIPTION IMPLICATIONS
Volume High The company produces over 60 Million Units of pharmaceuticals annually. Because of mass volume production, there is forward integration in the supply chain.
Variety High Variety is high because the company offers all pharmaceuticals. Because of a high variety, there is a high sale and also a diversified portfolio of catalogs.
Variation Low The variation in medicines is very low because the chemical composition remains fixed in all companies. Variation was dependent on outside conditions, but in this industry, no variation is allowed.
Visibility High The visibility of the company is high because of a diverse portfolio of a total of 35 labs all over the world (Ajayi, 2022). Global businesses have high visibility
  Quality: SQFD&C
Speed High Because of good suppliers, the speed of manufacturing products is high The speed of supplying consumer goods has to be high.
Quality High The quality has to be high because the goods are medications. TQM principle is followed critically.
Flexibility High Flexibility has to be high so as to make the company capable to adapt to changes A flexible internal environment is ensured.
Dependability High Dependability is high on suppliers for they provide raw materials at a fair cost. Dependability of company is on suppliers
Cost Low Cost is low Low cost is because of an efficient supply chain

Figure 1 Vision, purpose, 4Vs and SQFD&C analysis

4Vs

  1. Volume: Strong expansion across all of its key operational areas drove its annual revenue up 13.7 percent, from MAD1.81 billion ($189.6 million) in 2020 to more than MAD2.06 billion ($217 million) (Ajayi, 2022). Under the direction of Chairman and CEO Lamia Tazi, who owns 3.93 percent of the company, Sothema produces more than 60 million units of pharmaceuticals annually (Ajayi, 2022).
  2. Variety: the company has touched almost all varieties of pharmaceuticals. The group profited from the introduction of four new high-value items in 2021, which significantly increased sales and revenue during the review period (Ajayi, 2022).
  3. Variation: The reason for the low variation is the fixed chemical composition of the medicines.
  4. Visibility: The visibility of the company is high globally because the company has implemented an external expansion strategy in business. It oversees a varied portfolio of 35 international labs that produce and market goods across Europe, Sub-Saharan Africa, the Maghreb, and the Persian Gulf (Ajayi, 2022).

SQFD&C

  1. Speed: The reason behind high speed is to meet the demand for medicines, which are a part of consumer goods.
  2. Quality: Medications have to be made and the chemicals are to be formulated in a way, that is safer for the health of patients. That is why the quality is maintained by the company and is known for serving the patients.
  3. Flexibility: support from stakeholders and demand for changing systems and people’s needs, make it necessary for the pharmaceutical company to stay flexible. By ensuring flexibility, the company stays quality-oriented by focusing on the needs of patients and remains efficient in serving patients (Wadhwa, Madaan and Saxena, 2007).
  4. Dependability: The company is dependent on suppliers from different parts of the world, who are supplying to different international branches of the company.
  5. Cost: because of efficient supply chain and supplier relationship management, the company’s cost is low.

Leave a Comment